| Literature DB >> 30535300 |
Mark I Attard1,2, Timothy J W Dawes1,2,3, Antonio de Marvao1, Carlo Biffi1,4, Wenzhe Shi1,4, John Wharton2, Christopher J Rhodes2, Pavandeep Ghataorhe2, J Simon R Gibbs3, Luke S G E Howard5, Daniel Rueckert4, Martin R Wilkins2, Declan P O'Regan1.
Abstract
AIMS: We sought to identify metabolic pathways associated with right ventricular (RV) adaptation to pulmonary hypertension (PH). We evaluated candidate metabolites, previously associated with survival in pulmonary arterial hypertension, and used automated image segmentation and parametric mapping to model their relationship to adverse patterns of remodelling and wall stress. METHODS ANDEntities:
Keywords: cardiac magnetic resonance imaging; image segmentation; machine learning; metabolomics; pulmonary hypertension; wall stress
Mesh:
Year: 2019 PMID: 30535300 PMCID: PMC6529902 DOI: 10.1093/ehjci/jey175
Source DB: PubMed Journal: Eur Heart J Cardiovasc Imaging ISSN: 2047-2404 Impact factor: 6.875
Summary of baseline patient characteristics
| All PH patients | PH patients with metabolomics | Healthy controls | |
|---|---|---|---|
|
| 312 | 182 | 1985 |
| Age | 60.8 ± 15.9 | 58.6 ± 16.8 | 42.2 ± 13.2 |
| Female sex (%) | 47.1 | 51.1 | 55.2 |
| Body surface area (m2) | 1.86 ± 0.25 | 1.9 ± 0.3 | 1.82 ± 0.21 |
| Ethnicity, | |||
| Caucasian | 248 (79.5) | 152 (83.5) | 1379 (69.5) |
| South Asian | 14 (4.5) | 8 (4.4) | 305 (15.4) |
| African Black | 20 (6.4) | 7 (3.8) | 211 (10.6) |
| Others | 30 (9.6) | 15 (8.2) | 90 (4.5) |
| PH group | |||
| Pulmonary arterial hypertension | 99 (31.7) | 72 (39.6) | |
| PH due to left heart disease | 42 (13.5) | 7 (3.8) | |
| PH due to lung disease | 12 (3.8) | ||
| CTEPH | 150 (48.1) | 103 (56.6) | |
| PH with unclear mechanisms | 9 (2.9) | ||
| Functional | |||
| Six-minute walk distance (m) | 259.6 ± 157.8 | 276 ± 156.4 | |
| WHO/NYHA functional class, I/II/III/IV | 3/39/220/50 | 1/28/124/29 | |
| Baseline haemodynamics | |||
| Pulmonary capillary wedge pressure (mmHg) | 13.8 ± 6.1 | 10.9 ± 7.2 | |
| Mean pulmonary artery pressure (mmHg) | 44.5 ± 13.2 | 46.7 ± 13.3 | |
| Pulmonary vascular resistance (Woods units) | 8.5 ± 5.5 | 9.3 ± 5.9 | |
| Cardiac index (L/min/m2) | 2.4 ± 0.9 | 2.3 ± 0.9 | |
| Volumetry | |||
| RV end-diastolic volume (mL) | 194.1 ± 72.4 | 196.1 ± 69.1 | 164.0 ± 38.3 |
| RV end-diastolic volume (indexed) (mL/m2) | 105.2 ± 40 | 106.2 ± 39.4 | 89.3 ± 15.8 |
| RV stroke volume (mL) | 73.8 ± 28.3 | 69.8 ± 27.2 | 94.5 ± 20.2 |
| RV stroke volume (indexed), (mL/m2) | 40.1 ± 15.9 | 37.7 ± 15.4 | 51.6 ± 8.3 |
| RV ejection fraction (%) | 40.5 ± 13.6 | 37.8 ± 13.4 | 58.2 ± 5.9 |
| RV mass (g) | 49.2 ± 15.3 | ||
Variables are shown for the entire UK group and those with metabolomics as well as the healthy controls.
Values are expressed as mean ± standard deviation.
CTEPH, chronic thromboembolic PH; NYHA, New York Heart Association; PH, pulmonary hypertension; RV, right ventricle.
Dana Point classification.
Metabolite associations
| Metabolite | Pathway | RVM | RVEDV | RVM/RVEDV | RVEF | VMI | 3D wall stress |
|---|---|---|---|---|---|---|---|
| DHEA-S | Steroid | – | −0.26 | 0.18 | 0.31 | −0.21 | −0.4, 86.8% |
| N2DMG | Purine, Guanine | – | 0.18 | −0.17 | −0.28 | – | 0.34, 73.1% |
| N1MI | Purine, Hypo-Xanthine/Inosine | – | – | – | −0.21 | – | 0.28, 87.2% |
| 3H3MG | Mevalonate | – | – | – | −0.25 | 0.18 | 0.32, 81.7% |
| NAM | Met, Cys, SAM & Tau | – | – | −0.18 | −0.22 | – | 0.31, 81.9% |
| NFM | Met, Cys, SAM & Tau | – | 0.17 | −0.14 | −0.23 | −0.17 | 0.32, 69.7% |
| Fumarate | TCA cycle | – | 0.26 | −0.24 | −0.26 | 0.22 | – |
| 1L2EP | Phospholipid | – | – | – | – | – | – |
| SM | Sphingolipid | – | – | – | 0.2 | −0.24 | – |
| NAT | Met, Cys, SAM & Tau | – | 0.23 | −0.17 | −0.18 | – | – |
Adjusted P-value:
<0.05;
<0.01;
<0.001.
The relationship between metabolite concentration and phenotypic variables corrected for false discovery rate (presented as β coefficient with adjusted P-value, including area% for wall stress mapping).
3D, three-dimensional; DHEA-S, dehydroepiandrosterone sulfate; 3H3MG, 3-hydroxy-3-methylglutarate; 1L2EP, 1-linoleoyl-2-eicosapentaenoyl-GPC (18:2/20:5); NAM, N-acetylmethionine; NAT, N-acetyltaurine; NFM, N-formylmethionine; N1MI, N1-methylinosine; N2DMG, N2, N2-dimethylguanosine; RVEDV, right ventricular end-diastolic volume; RVEF, right ventricular ejection fraction; RVM, right ventricular mass; RVM/RVEDV, RVM corrected for RVEDV; VMI, ventricular mass index; SM, sphingomyelin (d18:1/20:0, d16:1/22:0); –, not significant.